- <![CDATA[Combination Radiopharmaceutical Approaches in Metastatic Castration-Resistant Prostate Cancer]]><![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss emerging combination strategies involving radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC), with a focus on t…onclive · 2mo ago↗ source
- <![CDATA[Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]><![CDATA[Dr. Pedro Barata and Dr. Johann De Bono open the discussion by reviewing the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC) and outlining…onclive · 2mo ago↗ source
- FDA’s leadership void leaves biotech with renewed ‘uncertainty’<figure><div><img src="https://imgproxy.divecdn.com/FNb_NTnh8G1qxJJ4-eXNdCf1X5Oo0JaGYzOyuwyRsW4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjEzNTk5ODA2XzEua…